Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026
Gene Solutions, a global biotechnology company, participated as a Premier Partner at the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD 2026), held virtually from July 7-9, 2026. The company presented data and expert perspectives on genomics, epigenomics, and artificial intelligence for comprehensive prenatal and women's health care. Key highlights included an industry symposium on advancing prenatal screening, real-world evidence from a study of 225,092 Asian pregnant women showing more than one in four carried at least one recessive condition, and emerging research on AI-driven multi-omic biomarkers for predicting gestational diabetes and preterm birth. Experts from Asia, Australia, Europe, and the US discussed opportunities and responsibilities in expanding genomic medicine.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection